The company has not filed an annual or quarterly report since its Q2 FY2023 10-Q, filed Aug 14, 2023. Its latest SEC filing is a SC 13G/A from Feb 12, 2024.
10-Q for Q2 FY2023, filed Aug 14, 2023
The sections below describe the company as of the FY2022 annual report.
Aims to bring a life sciences business to public markets through a merger or similar business combination.
10-K for FY2022, filed Mar 31, 2023We are an early stage blank check company formed as a Cayman Islands exempted company incorporated for the purpose of effecting an initial…View ↗
Early-stage companies need capital and market reach to maximize their commercial potential. We believe that biotechnology and life sciences…View ↗
We are a blank check company incorporated in the Cayman Islands on February 11, 2021 for the purpose of effecting a merger, share exchange…View ↗
10-Q for Q2 FY2023, filed Aug 14, 2023
$1.2MView ↗
8-K, filed Oct 4, 2023
On October 4, 2023, pursuant to Section 9.01(a) of the Business Combination Agreement, the parties to the Business Combination Agreement…View ↗
8-K, filed May 3, 2023
On May 2, 2023, BioPlus Acquisition Corp., a Cayman Islands exempted company (“BIOS”), Guardian Merger Subsidiary Corp., a Delaware…View ↗
Loading...
